 |
 |
 |
|
 |
|
 |
|
 |
 Stress, Mood, and Behavioral Disorders Stress-Related Affective Illness: Major Depression and Anxiety Disorders affect over 35 million Americans each year. Many patients with major depression or anxiety disorders (e.g., PTSD) show elevated levels of vasopressin that decline as illness improves. Depression affects 9.5% of adults annually, is increasingly common in adolescents, and is the leading cause of disability in the US and established market economies worldwide. Current drug therapies do not help some 60% of patients suffering from this disorder. Post-traumatic Stress Disorder (PTSD) affects some 8 million individuals in the US alone and is among the most common psychiatric conditions in the country. PTSD also is a major concern for military medicine. Currently approved drugs are repurposed antidepressants, which are ineffective and carry compliance and side effect issues. |
Azevan Pharmaceuticals, Inc. . is a clinical stage, small molecule drug development company developing novel therapeutics to treat disorders of stress, mood, and behavior. The Company’s first clinical compounds selectively block the effects of arginine vasopressin, a peptide neurohormone involved in the pathophysiology of major depression, intermittent explosive disorder, impulse control/anger disorders, and post-traumatic stress disorder (PTSD). Vasopressin receptor antagonists represent a novel mechanism of action for addressing these indications. |
|